Adv Healthc Mater. 2022 Nov 11. e2202460
Yu Liu,
Xu Liu,
Jiaxin Huang,
Yingying Shi,
Zhenyu Luo,
Junlei Zhang,
Xuemeng Guo,
Mengshi Jiang,
Xiang Li,
Hang Yin,
Bing Qin,
Guannan Guan,
Lihua Luo,
Yun Zhou,
Jian You.
Currently, mRNA-based tumor therapies are in full flow because in vitro-transcribed (IVT) mRNA has the potential to express tumor antigens to initiate the adaptive immune responses. However, the efficacy of such therapy relies heavily on the delivery system. Here, a Pardaxin-modified liposome loaded with tumor antigen-encoding mRNA and adjuvant (2',3'-cGAMP, (cyclic [G(2',5')pA(3',5')p])), termed P-Lipoplex-CDN is reported. Due to an non-lysosomal delivery route, the transfection efficiency on DCs is improved by reducing the lysosome disruption of cargos. The mRNA modified DCs efficiently induced tumor antigen-specific immune responses both in vitro and in vivo. As prophylactic vaccines, mRNA transfected DCs significantly delay the occurrence and development of tumors, and several immunized mice are even completely resistant to tumors. Interestingly, the efficacy depends on the major histocompatibility complex class I (MHC-I) expression level on tumor cells. Furthermore, epigenetic modification (decitabine, DAC) is applied as a combination strategy to deal with malignant tumor progression caused by deficient tumor MHC-I expression. This study highlighted the close relationship between mRNA-DCs vaccine efficacy and the expression level of tumor cell MHC-I molecules. Moreover, a feasible strategy for tumor MHC-I expression deficiency is proposed, which may provide clinical guidance for the design and application of mRNA-based tumor therapies. This article is protected by copyright. All rights reserved.
Keywords: MHC-I-restricted immunity; cancer therapy; cationic liposomes; epigenetic modification; mRNA-DCs